Core Curriculum - CCS Heart Failure with non-reduced EF Guidelines 2025: a Review

Dr. Ethan Lin PGY-4, Adult Cardiology University of Toronto Objectives: 1. To review the 2025 CCF/CHFS HFnrEF guidelines. 2. To summarize the key trials, including EMPEROR Preserved, DELIVER, FINEARTS-HF, PARAGON-HF, STEP-HFpEF, and SUMMIT 3. To compare the 2025 guideline to the prior 2017/2020/2021 CCS updates and to the 2023 ESC and 2022 AHA/ACC/HFSA guideline. 4. To discuss the practical implications of the new HFnrEF terminology. 5. To identify unresolved questions and future directions. Reference: Virani S, Zieroth S, Aleksova N , et al. Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF more than 40%). Canadian Journal of Cardiology, 41, 1857-1874 https://doi.org/10.1016/j.cjca.2025.0...